{"url_path":"/sec/imux/8-k/2026-05-13/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1280776/0001193805-26-000593-index.html","accession_number":"0001193805-26-000593","cik":"0001280776","ticker":"IMUX","issuer_name":"IMMUNIC, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1280776/0001193805-26-000593-index.html","primary_entity_key":"0001280776","primary_entity_name":"IMMUNIC, INC."},"word_count":146,"has_tables":true,"body_markdown":"**Item 2.02. Results of Operations and Financial Condition**\n\n \n\nOn May 13 2026, Immunic, Inc. (the “Company”)\nissued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the\nquarter ended March 31, 2026, and providing a corporate update (the “Press Release”).\n\n \n\nThe information contained in Item 2.02 of this\nCurrent Report on Form 8-K, including the Press Release, shall not be deemed “filed” for the purposes of Section 18 of the\nSecurities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the\nSecurities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference into any of the Company’s\nfilings with the Securities and Exchange Commission, except as shall be expressly set forth by specific reference in any such filing."}